MedPath

RESILIENCE GOVERNMENT SERVICES, INC.

RESILIENCE GOVERNMENT SERVICES, INC. logo
🇺🇸United States
Ownership
Subsidiary
Established
1999-01-01
Employees
251
Market Cap
-
Website
https://www.ologybio.com

Evaluating Technologies for Point-of-Care Blood Collections by Patients

Phase 1
Recruiting
Conditions
Healthy
Interventions
Device: Tasso+â„¢
First Posted Date
2024-07-18
Last Posted Date
2024-11-01
Lead Sponsor
Resilience Government Services, Inc.
Target Recruit Count
200
Registration Number
NCT06507566
Locations
🇺🇸

Victor Salib, Riverside, California, United States

Single or Repeat Dose of G03-52-01 in Adult Subjects

Phase 2
Active, not recruiting
Conditions
Healthy
Botulinum Toxin
Interventions
Drug: G03-52-01
Drug: Placebo
First Posted Date
2022-04-27
Last Posted Date
2024-10-28
Lead Sponsor
Resilience Government Services, Inc.
Target Recruit Count
625
Registration Number
NCT05348993
Locations
🇺🇸

AMR Mobile, Mobile, Alabama, United States

🇺🇸

AMR Tempe, Tempe, Arizona, United States

🇺🇸

AMR Fort Myers, Fort Myers, Florida, United States

and more 12 locations

Study to Evaluate the Safety and Efficacy of a Monoclonal Antibody Cocktail for the Prevention of COVID-19

Phase 2
Withdrawn
Conditions
COVID-19
Interventions
Drug: ADM03820
Other: Placebo
First Posted Date
2021-12-02
Last Posted Date
2023-02-03
Lead Sponsor
Resilience Government Services, Inc.
Registration Number
NCT05142527

Study of Adalimumab or Placebo in Patients With Mild to Moderate COVID-19 (COMBAAT)

Phase 3
Withdrawn
Conditions
Mild to Moderate COVID-19
Interventions
Drug: Placebo
Drug: Adalimumab
First Posted Date
2021-01-12
Last Posted Date
2022-03-03
Lead Sponsor
Resilience Government Services, Inc.
Registration Number
NCT04705844

Study of Monoclonal Antibody Cocktail Being Tested for the Prevention of COVID-19

Phase 1
Completed
Conditions
SARS-CoV-2
Interventions
Drug: ADM03820
Other: Placebo
First Posted Date
2020-10-19
Last Posted Date
2023-12-01
Lead Sponsor
Resilience Government Services, Inc.
Target Recruit Count
48
Registration Number
NCT04592549
Locations
🇺🇸

PMG Research of Winston-Salem, LLC, Winston-Salem, North Carolina, United States

🇺🇸

ICON Early Phase Services, LLC, San Antonio, Texas, United States

Study to Evaluate Safety and PK of a Single IM Dose of G03-52-01 vs Placebo in Adult Subjects

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: G03-52-01
Drug: Placebo
First Posted Date
2019-11-20
Last Posted Date
2024-10-04
Lead Sponsor
Resilience Government Services, Inc.
Target Recruit Count
40
Registration Number
NCT04171115
Locations
🇺🇸

ICON Early Phase Services, San Antonio, Texas, United States

Study to Evaluate Safety and PK of NTM-1634 vs Placebo Administered Intravenously in Healthy Adults

Phase 1
Completed
Conditions
Healthy
Interventions
Drug: NTM-1634
Drug: Placebo
First Posted Date
2017-02-08
Last Posted Date
2020-02-05
Lead Sponsor
Resilience Government Services, Inc.
Target Recruit Count
25
Registration Number
NCT03046550
Locations
🇺🇸

ICON Early Phase Services, LLC, San Antonio, Texas, United States

Japanese Pediatric H5N1 Vaccine Study

Phase 3
Completed
Conditions
Influenza
Interventions
Biological: H5N1 (Pre-)Pandemic Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated)
First Posted Date
2013-07-30
Last Posted Date
2015-10-09
Lead Sponsor
Resilience Government Services, Inc.
Target Recruit Count
60
Registration Number
NCT01911754
Locations
🇯🇵

Minami Clinic, Kagoshima-shi, Kagoshima-ken, Japan

🇯🇵

Shibahara Tahara Hospital, Kagoshima-shi, Kagoshima-ken, Japan

H5N1 Vaccine Study in Japanese Elderly Population Aged 65 Years and Older

Phase 3
Completed
Conditions
Influenza
Interventions
Biological: H5N1 Influenza Vaccine (Whole Virion, Vero Cell-Derived, Inactivated), non-adjuvanted formulation
First Posted Date
2013-01-23
Last Posted Date
2015-10-09
Lead Sponsor
Resilience Government Services, Inc.
Target Recruit Count
91
Registration Number
NCT01774032
Locations
🇯🇵

PS Clinic, Fukuoka City, Japan

🇯🇵

Osaka Pharmacology Clinical Research Hospital (OPHAC Hospital), Osaka City, Japan

Additional 6-Month Safety Follow-up After Completion of Precursor Study 880801

Phase 3
Completed
Conditions
Prophylaxis of Ross River Virus Infection
Interventions
Biological: Ross River Virus (RRV) Vaccine
First Posted Date
2012-05-24
Last Posted Date
2015-10-09
Lead Sponsor
Resilience Government Services, Inc.
Target Recruit Count
1146
Registration Number
NCT01604746
Locations
🇦🇺

St. Vincent´s Hospital, Darlinghurst, New South Wales, Australia

🇦🇺

Holdsworth House Medical Practice, Darlinghurst, New South Wales, Australia

🇦🇺

National Centre for Immunisation Research & Surveillance, The Children´s Hospital Westmead, Westmead, New South Wales, Australia

and more 10 locations
© Copyright 2025. All Rights Reserved by MedPath